U.S. Markets closed

Adaptimmune Therapeutics plc (ADAP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.9300+0.0400 (+1.38%)
At close: 04:00PM EST
2.9300 0.00 (0.00%)
After hours: 04:35PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.8900
Bid2.8800 x 2200
Ask2.9200 x 1000
Day's Range2.6800 - 2.9500
52 Week Range2.6800 - 7.3400
Avg. Volume876,018
Market Cap457.678M
Beta (5Y Monthly)1.99
PE Ratio (TTM)N/A
EPS (TTM)-1.0020
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.17
  • Motley Fool

    2 Cancer Stocks With Absurdly Low Valuations

    The potential for four or more interest rate hikes by the Federal Reserve over the course of 2022 has been weighing heavily on growth stocks of late. Investors are clearly pivoting toward safe havens like value and dividend stocks ahead of this perceived eventuality. Shares of the cancer specialists Adaptimmune Therapeutics (NASDAQ: ADAP) and Clovis Oncology (NASDAQ: CLVS) are both trading at absurdly low valuations following their steep downturns over the past several weeks.

  • Zacks

    4 Biotechs That Could Be Potential Takeover Targets in 2022

    We discuss a few companies like BioMarin (BMRN), Adaptimmune (ADAP), CRISPR Therapeutics (CRSP), and Alnylam Pharmaceuticals (ALNY) with solid product portfolios, deep pipelines which make them attractive candidates for a potential takeover in 2022.

  • Motley Fool

    Here's Why Biotech Stocks Adaptimmune Therapeutics, Agenus, and Ocugen All Crashed in November

    A mix of marketwide headwinds and company-specific events weighed on these three biotech stocks in November.